ID

32575

Beschreibung

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01025089

Link

https://clinicaltrials.gov/show/NCT01025089

Stichworte

Versionen (1)
  1. 07.11.18 07.11.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

7. November 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Thymoma NCT01025089

Englisch

Eligibility Thymoma NCT01025089

1 Formulare  
  1. StudyEvent: Eligibility
    1. Eligibility Thymoma NCT01025089
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
age>18
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
karnofsky performance status (kps) ≥ 70
Beschreibung

Karnofsky Performance Status

Datentyp

boolean

Alias
UMLS CUI [1]
C0206065
newly diagnosed or recurrent thymoma - who a, ab, b1, b2, or b340, or thymic carcinoma pathologically confirmed at mskcc, mdacc or city of hope
Beschreibung

Thymoma Newly Diagnosed WHO tumor classification | Thymoma malignant recurrent WHO tumor classification | Thymic Carcinoma

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0040100
UMLS CUI [1,2]
C1518321
UMLS CUI [1,3]
C1301142
UMLS CUI [2,1]
C0278848
UMLS CUI [2,2]
C1301142
UMLS CUI [3]
C0205969
no prior chemotherapy, radiotherapy, or surgical therapy (other than for diagnostic biopsy) for thymoma
Beschreibung

Absence Prior Chemotherapy Thymoma | Absence Prior radiation therapy Thymoma | Absence Operative Surgical Procedures Thymoma | Exception Biopsy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C1514457
UMLS CUI [1,3]
C0040100
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C0279134
UMLS CUI [2,3]
C0040100
UMLS CUI [3,1]
C0332197
UMLS CUI [3,2]
C0543467
UMLS CUI [3,3]
C0040100
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0005558
no prior treatment with cetuximab
Beschreibung

Cetuximab Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0995188
UMLS CUI [1,2]
C0332197
clinical masaoka stage ii (>5cm), iii, or iva(see appendix b), including suspected invasion of mediastinum, pericardium, lung, great vessels or chest wall, and/or pleural metastases normal marrow function: leukocytes ≥ 4,000/μl, absolute neutrophil count ≥ 1,500/μl, platelets ≥ 160,000/μl
Beschreibung

Masaoka Staging System | Tumor Invasion Suspected Mediastinum | Tumor Invasion Suspected Pericardium | Tumor Invasion Suspected Lung | Tumor Invasion Suspected Great vessels | Tumor Invasion Suspected Chest wall | Secondary malignant neoplasm of pleura | Bone Marrow function | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C3827366
UMLS CUI [2,1]
C1269955
UMLS CUI [2,2]
C0750491
UMLS CUI [2,3]
C0025066
UMLS CUI [3,1]
C1269955
UMLS CUI [3,2]
C0750491
UMLS CUI [3,3]
C0031050
UMLS CUI [4,1]
C1269955
UMLS CUI [4,2]
C0750491
UMLS CUI [4,3]
C0024109
UMLS CUI [5,1]
C1269955
UMLS CUI [5,2]
C0750491
UMLS CUI [5,3]
C0225991
UMLS CUI [6,1]
C1269955
UMLS CUI [6,2]
C0750491
UMLS CUI [6,3]
C0205076
UMLS CUI [7]
C0153678
UMLS CUI [8,1]
C0005953
UMLS CUI [8,2]
C0031843
UMLS CUI [9]
C0023508
UMLS CUI [10]
C0948762
UMLS CUI [11]
C0032181
adequate renal function, with creatinine ≤ 1.3 mg/dl or calculated creatinine clearance ≥60ml/min by cockcroft and gault equation using parameters of age, weight (kg), and baseline serum creatinine (mg/dl)
Beschreibung

Renal function | Creatinine measurement, serum | Estimation of creatinine clearance by Cockcroft-Gault formula

Datentyp

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2]
C0201976
UMLS CUI [3]
C2711451
adequate hepatic function: total bilirubin ≤1.5 mg/dl, ast ≤1.5x unl, alkaline phosphatase ≤1.5 un
Beschreibung

Liver function | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alkaline phosphatase measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C1278039
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201850
signed informed consent
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
effective contraception
Beschreibung

Contraceptive methods

Datentyp

boolean

Alias
UMLS CUI [1]
C0700589
medically operable
Beschreibung

Operable

Datentyp

boolean

Alias
UMLS CUI [1]
C0205188
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
evidence of distant metastatic disease (masaoka stage ivb)
Beschreibung

Distant metastasis Masaoka Staging System

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1269798
UMLS CUI [1,2]
C3827366
thymic carcinoid
Beschreibung

Thymic Carcinoid

Datentyp

boolean

Alias
UMLS CUI [1]
C1336746
patients must not be receiving any other investigational agents
Beschreibung

Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C0013230
concurrent or prior malignancy in the last 5 years other than non-melanoma skin cancer and in-situ carcinoma of the cervix
Beschreibung

Malignant Neoplasms | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0851140
known hiv-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with the study drugs. patients on medications known to alter cyp3a4
Beschreibung

Antiretroviral therapy Combination HIV Seropositivity | Drug Interactions Investigational New Drugs | Pharmaceutical Preparations Changing CYP3A4

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1963724
UMLS CUI [1,2]
C0205195
UMLS CUI [1,3]
C0019699
UMLS CUI [2,1]
C0687133
UMLS CUI [2,2]
C0013230
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C0392747
UMLS CUI [3,3]
C3714798
pregnant or breastfeeding women
Beschreibung

Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Thymoma NCT01025089

1 Formulare
  1. StudyEvent: Eligibility
    1. Eligibility Thymoma NCT01025089
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age>18
boolean
C0001779 (UMLS CUI [1])
Karnofsky Performance Status
Item
karnofsky performance status (kps) ≥ 70
boolean
C0206065 (UMLS CUI [1])
Thymoma Newly Diagnosed WHO tumor classification | Thymoma malignant recurrent WHO tumor classification | Thymic Carcinoma
Item
newly diagnosed or recurrent thymoma - who a, ab, b1, b2, or b340, or thymic carcinoma pathologically confirmed at mskcc, mdacc or city of hope
boolean
C0040100 (UMLS CUI [1,1])
C1518321 (UMLS CUI [1,2])
C1301142 (UMLS CUI [1,3])
C0278848 (UMLS CUI [2,1])
C1301142 (UMLS CUI [2,2])
C0205969 (UMLS CUI [3])
Absence Prior Chemotherapy Thymoma | Absence Prior radiation therapy Thymoma | Absence Operative Surgical Procedures Thymoma | Exception Biopsy
Item
no prior chemotherapy, radiotherapy, or surgical therapy (other than for diagnostic biopsy) for thymoma
boolean
C0332197 (UMLS CUI [1,1])
C1514457 (UMLS CUI [1,2])
C0040100 (UMLS CUI [1,3])
C0332197 (UMLS CUI [2,1])
C0279134 (UMLS CUI [2,2])
C0040100 (UMLS CUI [2,3])
C0332197 (UMLS CUI [3,1])
C0543467 (UMLS CUI [3,2])
C0040100 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0005558 (UMLS CUI [4,2])
Cetuximab Absent
Item
no prior treatment with cetuximab
boolean
C0995188 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Masaoka Staging System | Tumor Invasion Suspected Mediastinum | Tumor Invasion Suspected Pericardium | Tumor Invasion Suspected Lung | Tumor Invasion Suspected Great vessels | Tumor Invasion Suspected Chest wall | Secondary malignant neoplasm of pleura | Bone Marrow function | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement
Item
clinical masaoka stage ii (>5cm), iii, or iva(see appendix b), including suspected invasion of mediastinum, pericardium, lung, great vessels or chest wall, and/or pleural metastases normal marrow function: leukocytes ≥ 4,000/μl, absolute neutrophil count ≥ 1,500/μl, platelets ≥ 160,000/μl
boolean
C3827366 (UMLS CUI [1])
C1269955 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0025066 (UMLS CUI [2,3])
C1269955 (UMLS CUI [3,1])
C0750491 (UMLS CUI [3,2])
C0031050 (UMLS CUI [3,3])
C1269955 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0024109 (UMLS CUI [4,3])
C1269955 (UMLS CUI [5,1])
C0750491 (UMLS CUI [5,2])
C0225991 (UMLS CUI [5,3])
C1269955 (UMLS CUI [6,1])
C0750491 (UMLS CUI [6,2])
C0205076 (UMLS CUI [6,3])
C0153678 (UMLS CUI [7])
C0005953 (UMLS CUI [8,1])
C0031843 (UMLS CUI [8,2])
C0023508 (UMLS CUI [9])
C0948762 (UMLS CUI [10])
C0032181 (UMLS CUI [11])
Renal function | Creatinine measurement, serum | Estimation of creatinine clearance by Cockcroft-Gault formula
Item
adequate renal function, with creatinine ≤ 1.3 mg/dl or calculated creatinine clearance ≥60ml/min by cockcroft and gault equation using parameters of age, weight (kg), and baseline serum creatinine (mg/dl)
boolean
C0232804 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C2711451 (UMLS CUI [3])
Liver function | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alkaline phosphatase measurement
Item
adequate hepatic function: total bilirubin ≤1.5 mg/dl, ast ≤1.5x unl, alkaline phosphatase ≤1.5 un
boolean
C0232741 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201850 (UMLS CUI [4])
Informed Consent
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
Contraceptive methods
Item
effective contraception
boolean
C0700589 (UMLS CUI [1])
Operable
Item
medically operable
boolean
C0205188 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Distant metastasis Masaoka Staging System
Item
evidence of distant metastatic disease (masaoka stage ivb)
boolean
C1269798 (UMLS CUI [1,1])
C3827366 (UMLS CUI [1,2])
Thymic Carcinoid
Item
thymic carcinoid
boolean
C1336746 (UMLS CUI [1])
Investigational New Drugs
Item
patients must not be receiving any other investigational agents
boolean
C0013230 (UMLS CUI [1])
Malignant Neoplasms | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix
Item
concurrent or prior malignancy in the last 5 years other than non-melanoma skin cancer and in-situ carcinoma of the cervix
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
Antiretroviral therapy Combination HIV Seropositivity | Drug Interactions Investigational New Drugs | Pharmaceutical Preparations Changing CYP3A4
Item
known hiv-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with the study drugs. patients on medications known to alter cyp3a4
boolean
C1963724 (UMLS CUI [1,1])
C0205195 (UMLS CUI [1,2])
C0019699 (UMLS CUI [1,3])
C0687133 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
C0013227 (UMLS CUI [3,1])
C0392747 (UMLS CUI [3,2])
C3714798 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
pregnant or breastfeeding women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video